Desh Rakshak

Why is Desh Rakshak Aushdhalaya Ltd falling/rising?

As of 17-Jul, Desh Rakshak Aushdhalaya Ltd's stock price is stable at 31.00 but has significantly declined over the past year by -43.82%, indicating poor investor confidence and weak financial fundamentals. Contributing factors include decreased net sales, a low Return on Capital Employed, and reduced trading activity.

As of 17-Jul, Desh Rakshak Aushdhalaya Ltd's stock price is currently stable at 31.00, showing no change from the previous trading session. However, the stock has exhibited a significant decline over various periods, with a 1-year return of -43.82%, which is notably worse than the broader market's decline of -4.99%. This underperformance indicates a lack of investor confidence and suggests that the stock is falling.<BR><BR>Several factors contribute to this downward trend. The company has reported a weak long-term fundamental strength, highlighted by an average Return on Capital Employed (ROCE) of only 6.03%, which is below the industry average. Additionally, the company's net sales have decreased by 22.25% over the past nine months, and its ability to service debt is concerning, as indicated by a poor EBIT to Interest ratio of 0.95. <BR><BR>Moreover, the stock has shown erratic trading patterns, not trading on four out of the last twenty days, which reflects declining investor participation. The delivery volume has also dropped significantly, falling by 52.38% against the 5-day average, further indicating waning interest from investors. <BR><BR>While the stock has outperformed its sector by 1.41% today, the overall trend remains negative, with a year-to-date decline of 3.12% compared to the Sensex's -8.30%. The combination of weak financial performance, declining sales, and reduced trading activity suggests that Desh Rakshak Aushdhalaya Ltd is experiencing a falling stock price.

Which are the latest news on Desh Rakshak?

Should I buy, sell or hold Desh Rakshak Aushdhalaya Ltd?

What does Desh Rakshak do?

Desh Rakshak Aushdhalaya Ltd is a micro-cap pharmaceutical company specializing in Ayurvedic and herbal products, with recent net sales of 3 Cr and a market cap of INR 21 Cr. Established in 1901, it operates with a P/E of 35.00 and a debt-equity ratio of 0.13.

Overview:<BR>Desh Rakshak Aushdhalaya Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of pure Ayurvedic and herbal products.<BR><BR>History:<BR>The company was originally established in 1901 as a proprietorship by Shri Bhagwant Rai Jain and was converted into a Private Limited Company in July 1994. The latest quarterly results reported net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 3 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 21 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00 <BR>Industry P/E: 27 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.13 <BR>Return on Equity: 4.88% <BR>Price to Book: 1.62 <BR><BR>Contact Details:<BR>Address: Bhagwant Kuti, Kankhal Haridwar UTT : 249408 <BR>Tel: 91-1334-243833 <BR>Email: daral96@yahoo.in/dral95@yahoo.com <BR>Website: http://www.deshrakshak.com

How big is Desh Rakshak?

As of 10th June, Desh Rakshak Aushdhalaya Ltd has a market capitalization of 21.00 Cr, with recent net sales of 7.10 Cr and net profit of 0.57 Cr over the last four quarters.

As of 10th June, <BR><BR>Market Cap: Desh Rakshak Aushdhalaya Ltd has a market capitalization of 21.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 7.10 Cr, while the sum of Net Profit for the same period is 0.57 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds are valued at 9.96 Cr, and Total Assets amount to 17.98 Cr.

Who are in the management team of Desh Rakshak?

The management team of Desh Rakshak includes Tosh Kumar Jain (Chairman & Managing Director), Monika Jain and Arihant Kumar Jain (Whole-time Directors), Mohit Kumar (Independent Director), Sohini Bansal (Company Secretary & Compliance Officer), and Shruti Gupta (Additional Director).

The management team of Desh Rakshak includes the following individuals:<BR><BR>1. **Tosh Kumar Jain** - Chairman & Managing Director<BR>2. **Monika Jain** - Whole-time Director<BR>3. **Arihant Kumar Jain** - Whole-time Director<BR>4. **Mohit Kumar** - Independent Director<BR>5. **Sohini Bansal** - Company Secretary & Compliance Officer<BR>6. **Shruti Gupta** - Additional Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

Who are the peers of the Desh Rakshak?

Peers of Desh Rakshak include Ishita Drugs, Centuple Global, Parmax Pharma, and others. Centuple Global shows good management and the highest 1-year return at 105.84%, while Desh Rakshak has a 1-year return of -8.11%.

Peers: The peers of Desh Rakshak are Ishita Drugs, Centuple Global, Parmax Pharma, Dipna Pharmachem, Cian Healthcare, Starsource Multi, Zenith Health, Ortin Global, Colinz Labs.<BR><BR>Quality Snapshot: Below Average management risk is observed at Ishita Drugs, Parmax Pharma, Dipna Pharmachem, Cian Healthcare, Zenith Health, Ortin Global, and Colinz Labs, while management risk does not qualify at Starsource Multi. Good management risk is found at Centuple Global. Growth is excellent at Dipna Pharmachem, while below average growth is noted at Ishita Drugs, Parmax Pharma, Desh Rakshak, Cian Healthcare, and Ortin Global, and the rest. Good growth is observed at Centuple Global and Mono Pharmacare. Capital structure is good at Centuple Global and Colinz Labs, while below average capital structure is noted at Ishita Drugs, Parmax Pharma, Desh Rakshak, Dipna Pharmachem, Cian Healthcare, Zenith Health, Ortin Global, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Centuple Global at 105.84%, while the peer with the lowest is Dipna Pharmachem at -66.76%. Desh Rakshak's 1-year return is -8.11%, which is higher than Dipna Pharmachem's but lower than the rest. Additionally, the six-month return is negative for Dipna Pharmachem and Zenith Health.

Are Desh Rakshak Aushdhalaya Ltd latest results good or bad?

Desh Rakshak Aushdhalaya Ltd's latest results show strong profitability with a 233.33% increase in net profit and improved operating margins, but a 21.41% year-on-year revenue decline raises concerns about sustained growth. Overall, the results are good for profitability but bad for revenue performance.

Desh Rakshak Aushdhalaya Ltd's latest results present a mixed picture. In Q4 FY26, the company reported a net profit of ₹0.30 crores, which is a significant increase of 233.33% compared to the previous quarter. This indicates a strong sequential recovery in profitability. Additionally, the operating margin improved to 17.97%, up from 15.43% in the same quarter last year, suggesting better cost management.<BR><BR>However, the revenue figures tell a different story. The company generated ₹3.45 crores in revenue for Q4 FY26, which reflects a dramatic 146.43% increase from ₹1.40 crores in Q3 FY26. Despite this impressive quarter-on-quarter growth, the year-on-year comparison shows a decline of 21.41% from ₹4.39 crores in Q4 FY25, indicating ongoing demand challenges in its core Ayurvedic product portfolio.<BR><BR>Overall, while there are positive signs in terms of profitability and margin expansion, the significant year-on-year revenue decline raises concerns about the company's ability to sustain growth. Therefore, the results can be viewed as good in terms of profitability but bad regarding revenue performance.

When is the next results date for Desh Rakshak Aushdhalaya Ltd?

The next results date for Desh Rakshak Aushdhalaya Ltd is 29 May 2026.

The next results date for Desh Rakshak Aushdhalaya Ltd is scheduled for 29 May 2026.

Is Desh Rakshak overvalued or undervalued?

As of November 21, 2025, Desh Rakshak is fairly valued with a PE ratio of 37.17 and an EV to EBITDA of 14.92, showing strong performance compared to peers like Sun Pharma and Cipla, despite recent stock volatility and a YTD return of 159.81%.

As of 21 November 2025, Desh Rakshak's valuation grade has moved from expensive to fair, indicating a more favorable assessment of its market position. The company is currently fairly valued, with a PE ratio of 37.17, an EV to EBITDA of 14.92, and a Price to Book Value of 1.90. In comparison to its peers, Sun Pharma has a PE ratio of 36.98 and an EV to EBITDA of 24.43, while Cipla stands out as attractive with a PE ratio of 22.45 and an EV to EBITDA of 15.88.<BR><BR>Despite the recent volatility in its stock price, which has seen a significant YTD return of 159.81% compared to the Sensex's 9.08%, the company's valuation metrics suggest it is well-positioned within the pharmaceuticals and biotechnology sector. Overall, Desh Rakshak appears to be fairly valued in the current market environment.

How has been the historical performance of Desh Rakshak?

Desh Rakshak's historical performance shows a mixed trend, with net sales increasing slightly to 6.27 Cr in Mar'25, stable operating profit, and improved profits before and after tax. Despite rising total liabilities, the company has demonstrated resilience with gradual improvements in profitability and sales.

Answer:<BR>The historical performance of Desh Rakshak shows a mixed trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Desh Rakshak's net sales have shown a slight increase from 6.01 Cr in Mar'24 to 6.27 Cr in Mar'25, following a peak of 6.60 Cr in Mar'21. The total operating income also reflects this trend, reaching 6.27 Cr in Mar'25. The total expenditure, excluding depreciation, increased from 4.73 Cr in Mar'24 to 5.02 Cr in Mar'25. Operating profit (PBDIT) has remained relatively stable, with a slight decrease from 1.30 Cr in Mar'24 to 1.28 Cr in Mar'25. Profit before tax improved from 0.51 Cr in Mar'24 to 0.56 Cr in Mar'25, while profit after tax rose from 0.43 Cr to 0.48 Cr in the same period. The earnings per share (EPS) increased from 0.97 in Mar'24 to 1.08 in Mar'25. On the balance sheet, total liabilities increased from 15.74 Cr in Mar'23 to 16.32 Cr in Mar'24, with total assets also rising to 16.32 Cr. The cash flow from operating activities showed a positive change, with 1.00 Cr reported in Mar'24, while cash flow from investing activities remained negative at -1.00 Cr in Mar'22 and Mar'21. Overall, Desh Rakshak has demonstrated resilience in its financial performance, with gradual improvements in profitability and sales despite fluctuations in expenses and liabilities.

Who are the top shareholders of the Desh Rakshak?

The top shareholders of Desh Rakshak include promoters, with Tosh Kumar Jain holding 28.2% of the shares, and individual investors owning 35.58%. There are no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Desh Rakshak primarily include the promoters, with Tosh Kumar Jain holding the highest stake at 28.2%. Additionally, individual investors collectively own 35.58% of the company's shares. There are currently no mutual funds or foreign institutional investors (FIIs) holding shares in the company, and there are no pledged promoter holdings.

What is the technical trend for Desh Rakshak?

As of May 29, 2025, Desh Rakshak's technical trend is mildly bullish, supported by bullish MACD and moving averages, despite some bearish signals from the RSI and KST.

As of 29 May 2025, the technical trend for Desh Rakshak has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is also bullish, indicating positive momentum. However, the weekly RSI is bearish, suggesting some weakness in the short term. Bollinger Bands show a mildly bullish stance on both weekly and monthly time frames, supporting the overall mildly bullish trend. Daily moving averages are bullish, reinforcing the positive outlook. The KST indicates a mildly bearish trend on the weekly, but bullish on the monthly, which adds mixed signals. Dow Theory shows a mildly bearish trend on the weekly, with no trend on the monthly. Overall, the technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some bearish signals from the RSI and KST.

Has Desh Rakshak declared dividend?

No Dividend History Available